Willy Cowles

Cooley advised VNGR Beverage (doing business as poppi), a fast-growing prebiotic soda brand, on its acquisition by PepsiCo (Nasdaq: PEP) for $1.95 billion, including an additional potential earnout consideration subject to the achievement of certain performance milestones within a specified period after closing.

Cooley advised Archon Biosciences, a biotechnology company pioneering computationally designed antibody cages (AbCs) to unlock powerful therapeutic targets beyond the reach of existing modalities, on its $20 million seed financing led by Madrona Ventures.

Cooley advised ARCH Venture Partners, which co-led a $1 billion Series A funding round in Xaira Therapeutics. Partners Colleen Badgley, Danielle Naftulin and Dave Peinsipp led the Cooley team advising ARCH, a venture capital firm catalyzing discoveries that prevent, detect and cure disease.

Cooley advised Parse Biosciences on its $50 million Series C financing. Partner Sonya Erickson led the Cooley team advising Parse Biosciences, which develops single-cell sequencing products used by more than 1,000 labs worldwide.

Read more

Cooley advised CERo Therapeutics, an immunotherapy company, on its merger agreement with Phoenix Biotech Acquisition Corp.